# GeoVax to Present at the 36th Annual Roth Conference
Canonical URL: https://biopharmsignal.com/news/GOVX/geovax-to-present-at-the-36th-annual-roth-conference-2eb472bc
Ticker: GOVX
Company: GeoVax Labs
Source: GeoVax Labs
Published: 2024-03-12 13:00 EST
## Summary

via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies...

## Article Body
via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36th Annual Roth Conference, taking place in Dana Point, CA on March 17-19, 2024.

Presentation Details:

Presenter: David Dodd, Chairman & CEO Date/Time: March 18, 2024, 2:30 pm PT Location: Dana Point, CA Webcast Link: Roth Conference Webcast

The Company will also host in-person investor meetings. Institutional investors wishing to attend the conference and schedule meetings with GeoVax leadership should contact their Roth MKM representative.

About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com .

| Company Contact: |  | Investor Relations Contact: |  | Media Contact: |
| --- | --- | --- | --- | --- |
| info@geovax.com |  | paige.kelly@sternir.com |  | sr@roberts-communications.com |
| 678-384-7220 |  | 212-698-8699 |  | 202-779-0929 |
## Recent Company News
- 2024-12-09 14:00 EST — [GeoVax Receives Notice of Allowance For Cancer Vaccine Patent](https://biopharmsignal.com/news/GOVX/geovax-receives-notice-of-allowance-for-cancer-vaccine-patent-64188cc4) — Source: GeoVax Labs
- 2024-11-26 14:00 EST — [GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference](https://biopharmsignal.com/news/GOVX/geovax-to-present-at-the-noble-capital-markets-twentieth-annual-emerging-growth--80440681) — Source: GeoVax Labs
- 2024-11-19 14:00 EST — [GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia](https://biopharmsignal.com/news/GOVX/geovax-announces-positive-interim-data-review-for-phase-2-clinical-trial-of-covi-efe6dd0a) — Source: GeoVax Labs
- 2024-11-12 21:00 EST — [GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GOVX/geovax-reports-third-quarter-2024-financial-results-and-provides-business-update-44c641df) — Source: GeoVax Labs
- 2024-11-05 14:00 EST — [GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024](https://biopharmsignal.com/news/GOVX/geovax-to-report-third-quarter-2024-financial-results-and-provide-corporate-upda-37cc2e92) — Source: GeoVax Labs
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)